person · Reporting owner

Stark David Matthew

Disclosed activity across 2 companies

Tapewire entity: 37708
SEC CIK: 0001722360

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Exec. VP Chief Legal Officer	March 06, 2023	March 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date March 06, 2023 · Filed March 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,974.39	Last balance in matching sequence After 2023-03-07 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2023-03-06 · Sale · Disposed 16,491 · Balance 52,449.39 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2023-03-07 · Sale · Disposed 49,475 · Balance 2,974.39 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Assertio Holdings, Inc.

Report date June 16, 2026 · Filed June 16, 2026

Section 16 reporting ended · disclosed 2026-06-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Other · Disposed 11,420 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.15	Direct	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26	Direct	Reported balance After 2026-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]

F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 16, 2026 22:25 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	Disposition to issuerStock Option (Right to Buy) · Derivative	5,415	Not disclosed Strike: $9.26	Not disclosed	Disclosure SEC source: 0001104659-26-074739 · tm2618077-2_4seq1.xml · derivative · entry 3 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,415 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document
June 16, 2026 Filed Jun 16, 2026 22:25 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	Disposition to issuerStock Option (Right to Buy) · Derivative	5,415	Not disclosed Strike: $15.15	Not disclosed	Disclosure SEC source: 0001104659-26-074739 · tm2618077-2_4seq1.xml · derivative · entry 2 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,415 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. Read SEC document
June 16, 2026 Filed Jun 16, 2026 22:25 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	OtherCommon Stock	11,420	$0.00	$0.00	Disclosure SEC source: 0001104659-26-074739 · tm2618077-2_4seq1.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2 · shares: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3 · shares: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. Read SEC document
May 05, 2026 Filed May 6, 2026 22:06 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantCommon Stock	4,851	$0.00	$0.00	Disclosure SEC source: 0001104659-26-056418 · tm2613761-5_4seq1.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,420 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2026 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. F2 · balance_after: On December 26, 2025, the Issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document
November 10, 2025 Filed Nov 12, 2025 23:00 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	SaleCommon Stock	8,959	$0.76	$6,806.15	Disclosure SEC source: 0001104659-25-110557 · tm2530939-1_4seq1.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,541 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2024. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on November 10, 2025, at prices ranging from $0.7544 to $0.7668 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document
May 07, 2025 Filed May 9, 2025 22:03 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantStock Option (right to buy) · Derivative	81,225	$0.00 Strike: $0.62	$0.00	Disclosure SEC source: 0001104659-25-046870 · tm2514518-5_4seq1.xml · derivative · entry 2 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2035-05-07 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock Options that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document
May 07, 2025 Filed May 9, 2025 22:03 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantCommon Stock	53,750	$0.00	$0.00	Disclosure SEC source: 0001104659-25-046870 · tm2514518-5_4seq1.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,500 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2025 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document
November 07, 2024 Filed Nov 12, 2024 23:01 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantStock Option (right to buy) · Derivative	81,225	$0.00 Strike: $1.01	$0.00	Disclosure SEC source: 0001104659-24-116977 · tm2428139-2_4seq1.xml · derivative · entry 2 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2034-11-07 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock options were granted on the date of Mr. Stark's initial appointment to the Issuer's Board of Directors in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. One-third of these stock options are scheduled to vest on each of November 7, 2025, 2026 and 2027, assuming continued service through the applicable vesting date. Read SEC document
November 07, 2024 Filed Nov 12, 2024 23:01 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantCommon Stock	53,750	$0.00	$0.00	Disclosure SEC source: 0001104659-24-116977 · tm2428139-2_4seq1.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,750 F1 · shares: Restricted stock units were granted on the date of Mr. Stark's initial appointment to the Issuer's Board of Directors in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. One-third of these restricted stock units are scheduled to vest on each of November 7, 2025, 2026 and 2027, assuming continued service through the applicable vesting date. Read SEC document
March 07, 2023 Filed Mar 8, 2023 21:05 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	49,475	$9.43	$466,445.35	Disclosure SEC source: 0001209191-23-017161 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:05 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	16,491	$9.93	$163,770.47	Disclosure SEC source: 0001209191-23-017161 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,449.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	20,199	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · derivative · entry 7 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,400 Underlying: Ordinary Shares · 20,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 20,199 vested on each of March 5, 2022 and March 5, 2023, 20,199 vesting on March 5, 2024, and 20,201 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 20,199 vested on each of March 5, 2022 and March 5, 2023, 20,199 vesting on March 5, 2024, and 20,201 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	20,199	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · nonDerivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,940.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	31,836	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · derivative · entry 6 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,509 Underlying: Ordinary Shares · 31,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 31,836 vested on March 4, 2023, 31,836 vesting on each of March 4, 2024 and March 4, 2025 and 31,837 vesting on March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 31,836 vested on March 4, 2023, 31,836 vesting on each of March 4, 2024 and March 4, 2025 and 31,837 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	13,931	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · derivative · entry 5 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vested on each of March 4, 2021 and March 4, 2022, and 13,931 vested on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	31,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,741.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	13,931	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,905.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	94,621	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016721 · doc4.xml · derivative · entry 4 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,621 Underlying: Ordinary Shares · 94,621 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 23,655 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 23,656 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 23,655 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 23,656 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	44,953	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · derivative · entry 6 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 44,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F6 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	18,430	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · derivative · entry 5 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,430 Underlying: Ordinary Shares · 18,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 18,430 vesting on February 28, 2024. F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 18,430 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	44,953	$9.89	$444,432.33	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · nonDerivative · entry 4 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	44,953	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · nonDerivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,927.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	18,430	$9.89	$182,210.04	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:38 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	18,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-014442 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,404.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
February 07, 2023 Filed Feb 9, 2023 12:06 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	44,953	$0.00	$0.00	Disclosure SEC source: 0001209191-23-007954 · doc4.xml · derivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,953 Underlying: Ordinary Shares · 44,953 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 28, 2022 Filed Jul 29, 2022 11:02 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	58,163	$9.04	$525,589.95	Disclosure SEC source: 0001209191-22-043422 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.035 to $9.04, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 07, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	9,057	$7.37	$66,720.20	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 6 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,137.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	20,199	$0.00	$0.00	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · derivative · entry 10 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,599 Underlying: Ordinary Shares · 20,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 20,199 having vested on March 5, 2022, 20,199 vesting on each of March 5, 2023 and March 5, 2024, and 20,201 vesting on March 5, 2025. F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 20,199 having vested on March 5, 2022, 20,199 vesting on each of March 5, 2023 and March 5, 2024, and 20,201 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	20,199	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 5 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,194.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	127,345	$0.00	$0.00	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · derivative · entry 9 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,345 Underlying: Ordinary Shares · 127,345 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 31,836 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 31,837 vesting on March 4, 2026. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 31,836 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 31,837 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	13,930	$0.00	$0.00	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · derivative · entry 8 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,931 Underlying: Ordinary Shares · 13,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	37,939	$0.00	$0.00	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · derivative · entry 7 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	6,246	$7.48	$46,735.70	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 4 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,995.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	13,930	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,241.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	17,008	$7.48	$127,262.36	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,311.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	37,939	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-017063 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,319.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:54 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	18,430	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014475 · doc4.xml · derivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,860 Underlying: Ordinary Shares · 18,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 18,430 having vested on each of February 28, 2021 and February 28, 2022, and 18,430 vesting on each of February 28, 2023 and February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 18,430 having vested on each of February 28, 2021 and February 28, 2022, and 18,430 vesting on each of February 28, 2023 and February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:54 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	6,452	$8.14	$52,533.47	Disclosure SEC source: 0001209191-22-014475 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,380.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:54 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	18,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-014475 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,832.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	12,538	$0.00	$0.00	Disclosure SEC source: 0001209191-22-008418 · doc4.xml · derivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 12,538 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 12,538 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	6,110	$9.06	$55,357.82	Disclosure SEC source: 0001209191-22-008418 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,402.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	12,538	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-008418 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,512.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
February 08, 2022 Filed Feb 10, 2022 21:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	37,939	$0.00	$0.00	Disclosure SEC source: 0001209191-22-008418 · doc4.xml · derivative · entry 4 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,939 Underlying: Ordinary Shares · 37,939 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. Read SEC document
May 11, 2021 Filed May 13, 2021 11:48 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	37,884	$0.00	$0.00	Disclosure SEC source: 0001209191-21-032254 · doc4.xml · derivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 11, 2021 Filed May 13, 2021 11:48 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	37,884	$10.22	$387,125.23	Disclosure SEC source: 0001209191-21-032254 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.205 to $10.230, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
May 11, 2021 Filed May 13, 2021 11:48 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	37,884	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-032254 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,858.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
March 05, 2021 Filed Mar 8, 2021 21:12 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	80,798	$0.00	$0.00	Disclosure SEC source: 0001209191-21-018534 · doc4.xml · derivative · entry 4 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,798 Underlying: Ordinary Shares · 80,798 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 20,199 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024, and 20,201 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 20,199 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024, and 20,201 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:12 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	13,930	$0.00	$0.00	Disclosure SEC source: 0001209191-21-018534 · doc4.xml · derivative · entry 3 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,861 Underlying: Ordinary Shares · 13,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 13,930 vesting on each of March 4, 2021 and March 4, 2022 and 13,931 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:12 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	SaleOrdinary Shares	13,930	$10.57	$147,185.77	Disclosure SEC source: 0001209191-21-018534 · doc4.xml · nonDerivative · entry 2 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974.39 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:12 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	13,930	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-018534 · doc4.xml · nonDerivative · entry 1 Stark David Matthew · CIK 0001722360 · Exec. VP Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,904.39 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.